CN Patent

CN107012201A — 用于痤疮的新th17分化标志物及其用途

Assigned to Galderma Research and Development SNC · Expires 2017-08-04 · 9y expired

What this patent protects

本发明提供了RORγt或RORα的用途以及其用于诊断痤疮和/或筛选Th17分化的抑制剂，特别是在抑制RORγt或RORα中的用途以及这些筛选到的抑制剂在痤疮治疗中的用途。

USPTO Abstract

本发明提供了RORγt或RORα的用途以及其用于诊断痤疮和/或筛选Th17分化的抑制剂，特别是在抑制RORγt或RORα中的用途以及这些筛选到的抑制剂在痤疮治疗中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107012201A
Jurisdiction
CN
Classification
—
Expires
2017-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Galderma Research and Development SNC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.